Have A Question?
Contact us
UK Ireland
T: 44 (0) 1707 37 22 11
T: 353 (0) 16 40 18 18

Sanofi invests to expand biologics site in Belgium 19 April 2016

Expanding manufacturing and commercial capabilities

Sanofi has announced a €300 million investment to expand its site in Geel, Belgium. The investment furthers Sanofi's commitment to driving the future of biologics by expanding manufacturing and commercial capabilities in order to ensure quality, capacity, and scale.

Through the investment, Sanofi plans to adapt and expand existing production capabilities to support Sanofi's pipeline of monoclonal antibodies. Updates to the existing facility will include the development of new laboratories focused on quality control and manufacturing sciences.

Sanofi and its specialty care global business unit, Sanofi Genzyme, have already invested €600 million in the Geel site, which began industrial biotech activities in 2001. The site is currently responsible for the global production of a protein therapy for Pompe disease, a rare, genetic muscular disease that is often fatal. The protein therapy is produced using cell cultures in large bioreactors, followed by a purification process.

Through this latest investment, the state-of-the-art facility will add more than 8000 m2 of manufacturing floor space, enabling the site to increase its overall production capacity and diversify to other drugs and therapeutic areas. In support of this expansion, Sanofi intends to recruit and leverage the expertise of highly-skilled biotechnology professionals to fulfill a range of job functions. 

As part of the company's strategic roadmap, Sanofi aims to launch several biologics in the upcoming years, pairing technology, cutting-edge manufacturing and operations capabilities to deliver high-quality products that could improve patient outcomes.